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Abstract
Changes in brain amyloid burden have been shown to relate to Alzheimer’s disease pathology, and are believed to precede
the development of cognitive decline. There is thus a need for inexpensive and non-invasive screening methods that are
able to accurately estimate brain amyloid burden as a marker of Alzheimer’s disease. One potential method would involve
using demographic information and measurements on plasma samples to establish biomarkers of brain amyloid burden; in
this study data from the Alzheimer’s Disease Neuroimaging Initiative was used to explore this possibility. Sixteen of the
analytes on the Rules Based Medicine Human Discovery Multi-Analyte Profile 1.0 panel were found to associate with [11C]-
PiB PET measurements. Some of these markers of brain amyloid burden were also found to associate with other AD related
phenotypes. Thirteen of these markers of brain amyloid burden – c-peptide, fibrinogen, alpha-1-antitrypsin, pancreatic
polypeptide, complement C3, vitronectin, cortisol, AXL receptor kinase, interleukin-3, interleukin-13, matrix metalloprotei-
nase-9 total, apolipoprotein E and immunoglobulin E – were used along with co-variates in multiple linear regression, and
were shown by cross-validation to explain w30% of the variance of brain amyloid burden. When a threshold was used to
classify subjects as PiB positive, the regression model was found to predict actual PiB positive individuals with a sensitivity of
0.918 and a specificity of 0.545. The number of APOE E 4 alleles and plasma apolipoprotein E level were found to contribute
most to this model, and the relationship between these variables and brain amyloid burden was explored.
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Introduction
The failure of several clinical trials targeting brain amyloid
deposition in patients with Alzheimers disease (AD) has led to the
suggestion that these agents may be useful if targeted at older
individuals in pre-symptomatic stages of the disease [1,2].
Screening methods that accurately identify at-risk non-demented
older individuals who are most likely to benefit from such
treatments will therefore represent a major advance in our ability
to effectively test these disease-modifying treatments [3]. If clinical
trials of amyloid lowering interventions were successful in the pre-
symptomatic stages of AD, then there would be a desire to identify
non-demented elderly individuals with elevated brain amyloid
burden who could potentially benefit from early intervention.
However identifying suitable individuals poses a great challenge in
terms of feasibility and cost. To date, the two methods that are
most likely to be useful in estimating levels of brain amyloid
burden are in vivo imaging with positron emission tomography
(PET) using radioligands binding to fibrillar amyloid beta (Ab),
such as [11C] Pittsburgh B compound (PiB), and assays of Ab levels
in cerebrospinal fluid (CSF) [4,5]. However, both these methods
have inherent drawbacks that limit their utility as screening tools,
especially in resource-poor settings. While PET scanning is
expensive and limited to specialised centres, lumbar puncture to
obtain CSF is associated with some patient discomfort and is
unlikely to be used in primary health care centres to routinely
screen large numbers of elderly patients. An inexpensive, non-
invasive screening method that accurately estimates brain amyloid
burden would therefore fulfil a critical unmet need in the care of
the elderly.
The identification of blood-based biomarkers associated with
AD diagnosis [6–9] or distinct endophenotypes of AD pathology
such as brain atrophy [10–12], hippocampal metabolite abnor-
malities [13] and amyloid burden [14], have previously been
reported. In these studies, proteomic analyses were combined with
neuroimaging methods to identify plasma signals associated with
measures of AD pathology. In this study, a different strategy was
used by examining the association between brain amyloid burden
and a panel of 146 plasma analytes – proteins, complexes and
metabolites – measured by Rules Based Medicine, Inc. (RBM)
(Austin, TX) using the Human Discovery Multi-Analyte Profile
(MAP) 1.0 panel and a Luminex 100 platform. Some of the
analytes on this panel, such as apolipoprotein E (APOE) and
complement C3 have previously been shown to associate with
brain amyloid burden [14,15], while others are associated with
other diseases. These assays were performed in plasma samples
that were collected from participants in the Alzheimers Disease
Neuroimaging Initiative (ADNI; http://adni.loni.ucle.edu) study
who also underwent [11C]-PiB PET imaging for quantification of
fibrillar brain amyloid burden. The main aim of this study was to
ask whether concentrations of a panel of plasma proteins and
metabolites might accurately reflect the extent of fibrillar amyloid
in the brain. A secondary aim was to understand the relationship
between the number of APOE E 4 alleles and plasma based markers
of brain amyloid burden.
Results
RBM analytes associate with Ab levels in the brain
Levels of analytes measured by the RBM Human Discovery
MAP 1.0 from ADNI plasma samples were compared to fibrillar
amyloid in the RBM-PiB PET cohort (N=71). Characteristics of
this subcohort are summarised in Table 1 where it can be seen that
brain amyloid burden was almost significantly different at the 0.05
level between diagnostic groups (Kruskal-Wallis (KW) x2 test p-
value 0.055). The distribution of brain amyloid burden in the
RBM-PiB PET cohort is shown in Figure S1. In the slightly larger
ADNI-PiB PET cohort (i.e. all ADNI subjects with [11C] PiB-PET
scans performed at baseline), whose sample characteristics are
shown in Table S1, brain amyloid burden was found to be
significantly different across diagnostic groups (KW p-value 0.022).
The analytes most associated with brain amyloid burden in the
RBM-PiB PET cohort, after taking into account co-variates (age,
gender, years of education, number of APOE E 4 alleles and the
number of days between [11C]-PiB PET scan and plasma sample),
are shown in Table 2.
Prediction of brain amyloid burden using plasma RBM
analytes
To determine if a subset of the RBM panel was able to predict
fibrillar amyloid levels in the brain, multiple linear regression was
used. In this analysis the following subject co-variates were
included: age at plasma sample, years of education, gender, the
number of APOE E 4 alleles and the difference, in days, between
plasma sampling and [11C]-PiB PET scan date. Multiple linear
Table 1. Characteristics of the ADNI RBM-PiB PET cohort.
Diagnostic group (number of subjects)
Characteristics Control (3) MCI (52) AD (16) P-value
Subject age in years at time of plasma sample 77.4 [5.6] 75.4 [11.1] 72.3 [8.2] 0.290
(Median [IQR])
Sex (Male/Female) 1/2 37/15 10/6 0.263
Years of education (Median [IQR]) 13.0 [3.0] 16.0 [5.0] 16.0 [5.3] 0.398
Number of APOE E 4 alleles (0/1/2) 2/1/0 25/22/5 7/7/2 0.977
Days between [11C]-PiB PET scan and plasma sample (Median [IQR]) 5.0 [15.5] 23.5 [60.5] 21.5 [42.3] 0.288
Average PiB uptake 1.31 [0.108] 1.98 [0.723] 1.90 [0.438] 0.055
(Median [IQR])
Characteristics of the ADNI RBM-PiB PET subcohort by diagnostic group. P-values were calculated for differences across diagnostic groups using a Kruskal-Wallis x2 test
for continuous characteristics and simulated contingency p-values for categorical characteristics.
doi:10.1371/journal.pone.0044260.t001
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regression was applied to predict brain amyloid burden using these
co-variates only, giving a leave one out (LOO) cross validation
(CV) R2 of 0.040. When brain amyloid burden was regressed to
just the number of APOE E 4 alleles this gave a LOO CV R2 of
0.123. Then multiple linear regression was applied to predict brain
amyloid burden from both RBM analytes and co-variates; the
analysis was restricted to the 16 RBM analytes that had a partial
Spearmans rank correlation (SRC) uncorrected p-value v0.05
(Table 2) resulting in a LOO CV R2 of 0.276.
Overfitting was reduced by grouping correlated variables and
selecting one RBM analyte to represent each group (Figure 1); first
all the 16 RBM analytes were used, then analytes were removed
from the model one by one, in the order determined by clustering,
and LOO CV repeated. The order of analyte removal was: (1) von
willebrand factor, (2) leptin, (3) serum amyloid p-component, (4)
vitronectin, (5) interleukin-13, (6) component C3, (7) matrix
metalloproteinase-9 total, (8) immunoglobulin E (IgE), (9) APOE,
(10) pancreatic polypeptide, (11) alpha-1-antitrypsin, (12) interleu-
kin-3, (13) cortisol, (14) fibrinogen and finally (15) AXL receptor
tyrosine kinase.
The grouping that resulted in the highest LOO CV R2 over all
possible hierarchical clustering cut-offs was used (Figure 2). This
was achieved when 13 RBM analytes were used: c-peptide,
fibrinogen, alpha-1-antitrypsin, pancreatic polypeptide, comple-
ment C3, vitronectin, cortisol, AXL receptor tyrosine kinase,
interleukin-3, interleukin-13, matrix metalloproteinase-9 total,
APOE and IgE (LOO CV R2 0.310, permutation test p-value
4610{5). The 13 RBM analyte and co-variate model is able to
account for approximately a third of the variance of brain amyloid
burden. The relative importance of variables to the model is
shown in Figure 3; the number of APOE E 4 alleles was seen to be
the most important variable for the model, but RBM analytes
contribute more to the model than years of education or age. The
71 subjects brain amyloid burden was then dichotomised into
either PiB positive (brain amyloid burden w1.5) or PiB negative
(brain amyloid burden v1.5), based on a threshold used in
relevant literature [16]. Similarly, the subjects LOO CV predicted
brain amyloid burden, based on the 13 RBM and co-variate
model, was dichotomised into either predicted PiB positive
(predicted brain amyloid burden w1.5) or predicted PiB negative
(predicted brain amyloid burden v1.5). For each subject the
predicted and actual PiB classes (positive or negative) were
compared; the predicted PiB classes identified actual PiB positive
subjects with a sensitivity of 0.918 and a specificity of 0.545. It was
also found that removing all co-variates, except the number of
APOE E 4 alleles, from the 13 RBM and co-variate regression
model gave a similar but slightly improved predictive ability (LOO
CV R2 0.311).
Markers of brain amyloid burden associate with other
measures of AD pathology
The 16 RBM analytes found to associate with brain amyloid
burden in the ADNI RBM-PiB PET cohort were then tested for
association with other phenotypes known to relate to AD
pathology in the ADNI-RBM cohort (sample characteristics
shown in Table S2). In this analysis age, gender, years of
education and the number of APOE E 4 alleles were included in
partial correlation analysis. Subjects with missing values for a
relevant comparison were excluded. First the level of the markers
of brain amyloid burden were compared with the level of Ab1{42
in the CSF. Leptin was found to associate with CSF Ab1{42
(partial SRC 0.183, BH MTC p-value 0.0183). Additionally, when
multiple testing was not taken into account, vitronectin was
associated with CSF Ab1{42 (partial SRC 0.131, uncorrected p-
value 2.07610{2).
Markers of brain amyloid burden were then compared to AD
relevant brain regions as measured by structural magentic
resonance imaging (sMRI). The volume of the left and right
Table 2. RBM analytes associated with brain amyloid burden.
RBM analyte Gene name Uniprot ID
Partial SRC with
Ab P-value
Benjamini-Hochberg corrected p-
value
C-peptide INS P01308 20.310 0.010 0.351
Fibrinogen (a, b and c) FG(A/B/G) P02671 P02675
P02679
20.307 0.010 0.351
Alpha-1-antitrypsin SERPINA1 P01009 20.302 0.012 0.351
Pancreatic polypeptide PPY P01298 20.296 0.014 0.351
Complement C3 C3 P01024 20.296 0.014 0.351
Vitronectin VTN P04004 20.295 0.014 0.351
von Willebrand factor VWF P04275 20.287 0.017 0.363
Cortisol (NA) (NA) 0.271 0.025 0.412
Serum amyloid p-component APCS P02743 20.268 0.027 0.412
AXL receptor tyrosine kinase AXL P30530 0.266 0.028 0.412
Interleukin-3 IL3 P08700 0.261 0.032 0.412
Interleukin-13 IL13 P35225 0.252 0.038 0.412
Matrix metalloproteinase-9 total MMP9 P14780 20.250 0.040 0.412
APOE APOE P02649 20.248 0.042 0.412
Leptin LEP P41159 20.248 0.042 0.412
Immunoglobulin E (IgE) (NA) (NA) 20.243 0.046 0.424
Analytes with a partial SRC p-value ofv0.05 are shown. Benjamini-Hochberg corrected p-values were calculated to take into account the comparisons against all RBM
analytes.
doi:10.1371/journal.pone.0044260.t002
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hippocampi, and the thickness of the left and right entorhinal
cortices were used, as these regions are known to be important in
AD pathology [12]. Alpha-1-antitrypsin was found to associate at
the 5% significance level with the thickness of both the left (partial
SRC 20.132, BH MTC p-value 0.0289) and right (partial SRC
20.145, BH MTC p-value 9.82610{3) entorhinal cortices.
Additionally, leptin was found to associate with the thickness of
the right entorhinal cortex (partial SRC 0.124, BH MTC p-value
0.0264). Cortisol was found to associate at the 5% significance
level with the volume of both the left (partial SRC 20.158, BH
MTC p-value 2.71610{3) and right hippocampi (partial SRC
20.161, BH MTC p-value 2.07610{3).
Different cognitive tests, such as the Mini Mental State Exam
(MMSE) and Alzheimer’s Disease Assessment Scale-cognitive
subscale (ADAS-cog) 13, assess different aspects of cognitive
decline. The association between scores from these tests and levels
of markers of brain amyloid burden was analysed; 4/16 of the
markers of brain amyloid burden – alpha-1-antitrypsin (partial
SRC 20.145, BH MTC p-value 3.02610{3), complement C3
(partial SRC 20.189, BH MTC p-value 9.46610{5), cortisol
(partial SRC 20.162, BH MTC p-value 8.33610{4) and
fibrinogen (partial SRC 20.130, BH MTC p-value 8.28610{3)
– were found to associate with the total MMSE score at the 5%
level. In the same cohort (ADNI-RBM), three of these markers –
alpha-1-antitrypsin (partial SRC 0.172, BH MTC p-value 0.0403),
complement C3 (partial SRC 0.119, BH MTC p-value 0.0467)
and fibrinogen (partial SRC 0.111, BH MTC p-value 6.34610{4)
– were found to associate with the ADAS-cog 13 score at the 5%
significance level.
Levels of the 16 markers of brain amyloid burden were then
compared between different diagnostic groups (control, MCI and
AD) in the various cohorts, to assess whether these markers were
related to clinical diagnosis. It was found that half of the
biomarkers of brain amyloid burden measured – APOE (BH
MTC KW p-value 1.24610{9, AD/control median difference
(MD) 20.143), complement C3 (BH MTC KW p-value
8.88610{8, MCI/control MD 20.0483), cortisol (BH MTC
KW p-value 2.40610{3, AD/control MD 0.0366), interleukin-3
(BH MTC KW p-value 8.48610{3, AD/control MD 20.0670),
leptin (BH MTC KW p-value 8.48610{3, AD/control MD
20.112), pancreatic polypeptide (BH MTC KW p-value
1.92610{2, AD/control MD 0.122), alpha-1-antitrypsin (BH
MTC KW p-value 1.75610{7, AD/control MD 0.0300) and
vitronectin (BH MTC KW p-value 5.50610{3, AD/control MD -
0.0344) – significantly differ at the 5% level between diagnostic
groups.
Figure 1. Analyte correlations. Heatmaps of partial SRC between RBM analytes significantly associated (p-value v0.05) with brain amyloid
burden, taking into account: age, gender, years of education, number of APOE E 4 alleles and the difference, in days, between plasma sampling and
[11C]-PiB PET scan date. RBM analytes have been ordered by hierarchical clustering, the final cut-off is shown in purple. Variables that have been
grouped are shown in blue boxes, and the representative for each group is shown in a red box.
doi:10.1371/journal.pone.0044260.g001
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The effect of APOE genotype on APOE level in plasma
and brain amyloid burden
The number of APOE E 4 alleles and the level of APOE in
plasma were the two variables that contributed most to the
regression model. A number of studies have shown that APOE
level in plasma is affected by presence of APOE E 4 alleles
[14,15,17–19]. Additionally, Slooter et al., [17] have previously
shown that the difference in plasma APOE levels between AD and
control subjects is largely driven by the APOE genotype, and so the
interaction of these two variables was studied further. In the
ADNI-RBM cohort the number of APOE E 4 alleles was seen to
have a negative effect on plasma APOE levels (KW p-value
v2.20610{16, Table 3). The negative effect of APOE genotype on
plasma APOE levels in this ADNI subcohort was demonstrated
recently using Analysis of Variance (ANOVA) [20]. The analysis
presented here shows that this result holds when assumptions of
normality are dropped. The negative effect of the number of APOE
E 4 alleles on plasma APOE levels observed fits with the findings of
some literature [15,17,18], but is the opposite of the positive effect
seen by both Evans et al. and Thambisetty et al. (2010) [14,19].
Given the discrepancy between this finding and those in two
published studies, the relationship between the number of APOE E
4 alleles and plasma APOE levels was studied in an independent
cohort of 694 subjects (AddNeuroMed and King’s Health Partners
Dementia Case Register, ANM + KNPDCR). In the ANM +
KHPDCR cohort the number of APOE E 4 alleles was also seen to
have a negative effect on plasma APOE levels (KW p-value
v2.20610{16, Table 3). Both studies that have found a positive
relationship between APOE E 4 alleles on plasma APOE levels have
been conducted in cohorts of cognitively normal subjects [14,19],
which may account for this inconsistency. However, a similar
negative effect was found in the control subjects (who are
cognitively normal) of the ANM + KHPDCR cohort (KW p-
value 1.57610{4, Table 3). This suggests another factor, other
than cognitive decline, is responsible for the discrepancies between
these studies.
Given that the number of APOE E 4 alleles affects both plasma
APOE levels and brain amyloid burden, it is possible that the
number of APOE E 4 alleles confounds the association between
plasma APOE levels and brain amyloid burden. To test this,
partial correlation analysis was repeated excluding the number of
APOE E 4 alleles, this increased the correlation of plasma APOE
level and brain amyloid burden (partial SRC 20.393, p-value
6.9610{4), which indicated that the association is indeed partly
confounded by the number of APOE E 4 alleles.
Discussion
In this study, fibrillar amyloid beta levels, in ADNI subjects,
have been compared and related to the level of analytes on the
RBM panel in plasma. Brain amyloid burden appears to be
distributed bimodally in the RBM-PiB PET cohort, as has been
previously reported for a larger ADNI subcohort by Ewers et al.
[21]. Associations of C-peptide, fibrinogen, alpha-1-antitrypsin,
pancreatic polypeptide, complement C3, vitronectin, von will-
ebrand factor, cortisol, serum amyloid p-component, AXL
receptor tyrosine kinase, interleukin-3, interleukin-13, matrix
metallproteinase-9, APOE, leptin and immunoglobulin E with
brain amyloid burden have been found in this study. Some of these
markers of brain amyloid burden were also found to associate with
other AD related phenotypes, such as CSF Ab1{42, MRI features,
cognitive tests and diagnostic groups. In regression models it was
found that models including both RBM analytes and co-variates
performed better than those using only co-variate information,
suggesting that the RBM panel of analytes can be used as markers
of brain amyloid burden. Combining highly correlated variables
was found to reduce overfitting and led to a set of 13 RBM
analytes that together with co-variates could explainw30% of the
variance of brain amyloid burden and predict PiB positive
individuals with a high sensitivity. This result, and the increased
predictive accuracy of the 13 RBM model in comparison to using
Figure 2. Cross validation of multiple linear regression. Barplot
of the LOO CV R2 of multiple linear regressions of brain amyloid burden
against a range of RBM analytes and co-variates. Subsets of RBM
analytes that associated with brain amyloid levels with a p-valuev0.05
were used. Various subsets were chosen by hierarchical clustering at
various cutoffs, with the analyte most associated with brain amyloid
burden in each cluster chosen to represent that cluster. Age, gender,
years of education, the number of APOE E 4 alleles and the difference, in
days, between plasma sampling and [11C]-PiB PET scan were used as co-
variates.
doi:10.1371/journal.pone.0044260.g002
Figure 3. Relative importance in multiple linear regression.
Relative importance of variables used in multiple linear regression
assessed using the LMG relative importance score [51]. When all the
data is used to fit the model it explains 62.0% of the variance of the
brain amyloid burden, here the contribution of the variables used in this
model are shown.
doi:10.1371/journal.pone.0044260.g003
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only co-variates to predict fibrillar amyloid alone, indicate that
these analytes reflect levels of fibrillar amyloid in the brain.
The potential of APOE level in plasma to be used as a
biomarker for brain amyloid burden, previously shown in
Thambisetty et al. (2010) [14], is given support by this study.
However it should be noted that the association between plasma
APOE level and brain amyloid burden was seen to be positive in
that study and negative in this. This inconsistency may relate to
differences between the cohorts, for example the BLSA cohort
studied in Thambisetty et al. (2010) were selected to be cognitively
normal. This fits with the recent finding that plasma level of
APOE correlates negatively with brain amyloid burden in the
Australian Imaging, Biomarker and Lifestyle Flagship Study of
Ageing, which includes subjects suffering from AD [15]. Similarly,
the effect of the presence of APOE E 4 alleles on plasma APOE
level in the study presented here was found to be the opposite of
that found in both Thambisetty et al. (2010) and Evans et al.
[14,19], however it is the same as that seen in Slooter et al., Siest
et al. and Gupta et al. [15,17,18]. Additionally, this relation was
replicated in an independent cohort (ANM + KHPDCR) and it’s
control subcohort. This latter finding suggests that the differences
between the findings of these studies is not due to the subjects
cognitive status. The factor/s responsible for these inconsistencies
are not known, but the fact that strong associations are seen in all
studies is encouraging.
While no association between the level of RBM analytes in
plasma and brain amyloid burden was found to be significant at
the 5% level after multiple testing corrections, it should be noted
the cohort used (RBM-PiB PET) contained relatively few subjects
and that many analytes that associated significantly at the
uncorrected 0.05 level have known relations to AD pathology,
for example levels of APOE and complement C3 in plasma have
previously been found to associate with fibrillar amyloid levels in
the Baltimore Longitudinal Study of Aging (BLSA) cohort [14]. In
addition, some of these analytes were subsequently found to
associate with surrogate phenotypes of AD pathology in the larger
ADNI-RBM cohort, such as: diagnostic groups, MMSE score,
ADAS-cog 13 score, CSF Ab1{42 level, and the thickness and/or
volume of the entorhinal cortices. However, 7/16 of the markers
of brain amyloid burden – c-peptide, von Willebrand factor, serum
amyloid p-component, AXL receptor tyrosine kinase, interleukin-
13, matrix metalloproteinase-9 total and IgE – were not found to
associate with any of the surrogate phenotypes of AD pathology
that were tested. It should be noted that 5 of the 7 are linked to AD
in the literature (Table S3), only IgE and interleukin-13 have no
prior reported association. Most of these surrogate phenotypes,
except CSF Ab1{42, are believed to change at a later disease stage
than amyloid pathology, and so it is possible that the lack of
association of some of the markers with, for example, diagnostic
groups is due to the mixture of high and low brain amyloid burden
control subjects used. However, the lack of association of the
majority of the markers with CSF Ab1{42 levels is of greater
concern because CSF Ab1{42 levels are strongly associated with
brain amyloid burden [4,5]; this may indicate that we are over-
fitting the available data and further highlights the need for
datasets with larger sample sizes for future studies of markers of
brain amyloid burden.
While half of the markers associated with diagnostic groups, 3/8
of these markers – alpha-1-antitrypsin, pancreatic polypeptide and
interleukin-3 – had a median difference between AD (or MCI) and
control subjects that was of the opposite sign to the partial SRC
coefficient measuring their association with brain amyloid burden.
This result is surprising as brain amyloid burden is positively
associated with AD and MCI diagnosis groups. This discrepancy
could relate to the delay between these disease stages, and may
mean that the level of some of the markers in plasma changes
during Ab deposition and then changes again, but in the opposite
direction, before the onset of clinical symptoms. Similar u-shaped
profiles, but between subjects in different diagnostic groups, have
been observed (cross-sectionally) in the level of many leukocyte
transcripts during AD progression [22].
Partial correlation showed that the number of APOE E 4 alleles
partly confounded the association between APOE level in plasma
and brain amyloid burden; however, plasma APOE levels did help
a regression model predict brain amyloid burden and so further
study is required to get a clearer idea of the APOE E 4 independent
information conveyed by plasma APOE levels. This study has
revealed many novel potential markers of brain amyloid burden,
chosen to give APOE E 4 independent information, as well as
replicating findings from other studies. This will allow further
validation work that can test the replicability and clinical utility of
these markers.
In a previous study that used discovery proteomics to identify
proteins associated with brain amyloid levels, Thambisetty et al.
(2010) showed that levels of APOE and Complement C3 precursor
in plasma were different between subjects with high and low brain
amyloid burdens [14]. It was encouraging that both were seen to
be associated with brain amyloid burden in this study as well.
Complement C3 precursor has also been found to be associated
with atrophy of hippocampal volume, another imaging marker of
AD [11], and to have a role in plaque clearance in a mouse model
[23]. It has also been found along with vitronectin to be at
different levels in serum between control and AD subjects [6]. The
level of fibrinogen gamma was also found to be associated with
Table 3. The effect of APOE genotype on plasma APOE levels.
The plasma level in log mg/ml of APOE in
subjects with n APOE E 4 alleles (median [IQR])
Cohort n=0 n=1 n=2
Kruskal-Wallis x2 P-
value
ADNI-RBM 1.79 [0.200] 1.66 [0.203] 1.52 [0.233] ,2.20610216
ANM + KHPDCR 1.91 [9.7561022] 1.88 [9.0061022] 1.82 [7.0061022] ,2.20610216
ANM + KHPDCR
controls 1.9 [0.100] 1.88 [8.0061022] 1.83 [3.0061022] 1.5761024
Level of plasma APOE stratified by the subjects number of APOE E 4 alleles.
doi:10.1371/journal.pone.0044260.t003
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atrophy of hippocampal volume in Thambisetty et al. (2011) [11].
Fibrinogen alpha, beta and gamma are targeted by the same RBM
analyte and were found to associate with brain amyloid burden in
this study.
Of the 16 RBM analytes whose level in plasma associated with
brain amyloid burden, many have known relationships with
Alzheimer’s disease. The levels of the following have previously
been found to be different between control and AD subjects:
alpha-1-antitrypsin [9,24], APOE [9], cortisol [9,25,26], interleu-
kin-3 [27], matrix metalloproteinase-9 [9,28], pancreatic polypep-
tide [9,29], serum amyloid p-component [30] and von Willebrand
factor [31]. Serum amyloid p-component [32] and insulin [33]
have been shown to affect ‘AD’-like pathology in vitro. Interleukin-
3 [34] and leptin [35] have been found to affect the interaction of
neurons and Ab. Additionally, interleukin-13 has been found to be
produced in microglia in response to Ab [36]. More recently,
APOE and matrix metalloproteinase-9 have been shown to be
involved together in the breakdown of the blood brain barrier,
which can initiate neurodegeneration [37].
Given the relatively small number of subjects in this study it was
not practical to separate the subjects into training and test sets, to
assess the predictive accuracy of the regression model. Instead, k-
fold cross-validation was used, allowing more of the subjects to be
used for fitting the regression model. Generally it is advisable to
use 10-fold cross-validation because it has been found to have a
lower variance [38]. However, given the limited number of
samples available, a leave one out cross-validation approach was
used in this study to allow the maximal use of the subjects
available. Given the limited number of subjects on which the
model is based, it will be important in the future to study the
ability of these biomarkers to predict brain amyloid burden in an
independent cohort. Validation studies would benefit from greater
numbers of subjects and better sampling strategies. For example,
the distribution of brain amyloid burden in the RBM-PiB PET
subcohort is affected by the sampling strategy applied to select
control subjects for RBM measurements; only plasma of control
subjects with high CSF Ab1{42 were selected, for reasons
unrelated to the current study. This means that the resulting
model may not extrapolate to cognitively normal subjects with
high brain amyloid burden, this could be tested in a validation
study. Additionally, the use of only three control subjects may
make the regression model less likely to generalise to prediction of
brain amyloid burden in early Alzheimer’s disease.
In conclusion, analytes associating with brain amyloid burden
have the potential to act as biomarkers of early AD-related
pathology. In this study sixteen analytes were found to associate
with brain amyloid burden, including two (APOE and comple-
ment C3) that had had already been shown to associate with brain
amyloid burden in an independent cohort. Some of these analytes
were also found to associate with other AD related phenotypes in a
larger ADNI subcohort, such as: CSF Ab1{42, MRI features,
cognitive scores and diagnostic groups. Some of these analytes
were found to correlate highly with each other, and so a
representative set of thirteen analytes – c-peptide, fibrinogen,
alpha-1-antitrypsin, pancreatic polypeptide, complement C3,
vitronectin, cortisol, AXL receptor kinase, interleukin-3, interleu-
kin-13, matrix metalloproteinase-9 total, APOE and IgE – were
used along with subject age, gender, years of education, the
number of APOE E 4 alleles and sampling dates to predict brain
amyloid burden. The 13 analyte and co-variate model was found
by cross-validation to account for w30% of the variance of brain
amyloid burden, as opposed to * 4–13% using just co-variates
alone, showing the potential of plasma analytes as markers of brain
amyloid burden. The model was also able to predict PiB positive
individuals with a high sensitivity. The two variables with the
largest contribution to the model were found to be the number of
APOE E 4 alleles and plasma APOE level. The association of
plasma APOE level with brain amyloid burden was shown to be
partly confounded by the number of APOE E 4 alleles, highlighting
the importance of novel biomarkers that are less confounded by
the APOE genotype revealed by this study.
Materials and Methods
Ethics statement
Written informed consent was obtained from all participants in
ADNI and the study was conducted with prior institutional ethics
approval. Both ANM and KHPDCR were approved by the South
London and Maudsley NHS Foundation Trust ethics committee.
Ethics committee approval was also obtained at each of the
participating centres in accordance with the Alzheimers Associa-
tions published recommendations [39].
ADNI Data
Data used in the preparation of this article were obtained from
the ADNI database (adni.loni.ucla.edu). The ADNI was launched
in 2003 by the National Institute on Aging (NIA), the National
Institute of Biomedical Imaging and Bioengineering (NIBIB), the
Food and Drug Administration (FDA), private pharmaceutical
companies and non-profit organisations, as a $60 million, 5- year
public-private partnership. The primary goal of ADNI has been to
test whether serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to measure
the progression of mild cognitive impairment (MCI) and early
Alzheimers disease (AD). Determination of sensitive and specific
markers of very early AD progression is intended to aid
researchers and clinicians to develop new treatments and monitor
their effectiveness, as well as lessen the time and cost of clinical
trials.
The Principal Investigator of this initiative is Michael W.
Weiner, MD, VA Medical Center and University of California
San Francisco. ADNI is the result of efforts of many co-
investigators from a broad range of academic institutions and
private corporations, and subjects have been recruited from over
50 sites across the U.S. and Canada. The initial goal of ADNI was
to recruit 800 adults, ages 55 to 90, to participate in the research,
approximately 200 cognitively normal older individuals to be
followed for 3 years, 400 people with MCI to be followed for 3
years and 200 people with early AD to be followed for 2 years. For
up-to-date information, see www.adni-info.org.
Demographic (age, gender, years of education), genetic (number
of APOE E 4 alleles), diagnosis (control, MCI or AD at a given date)
and analyte (metabolite/protein/complex) levels in plasma were
compared with brain amyloid burden (or other markers of AD
pathology such as: CSF Ab1{42 level, MRI features, cognitive
scores or diagnostic groups). Diagnoses were recorded for each
subject at each visit. Plasma and CSF were collected from fasted
subjects using the procedures described previously [29,40]. Levels
of 190 analytes were measured from subject plasma using the
Rules Based Medicine (RBM, rulesbasedmedicine.com, Austin,
TX) Human Discovery Multi-Analyte Profile (MAP) 1.0 panel and
a Luminex 100 platform [41]. Measurements of 44 analytes were
excluded on the basis of quality control, leaving 146 analytes in the
subsequent analysis. The levels of all 146 analytes (except:
apolipoprotein H, complement factor H, E selectin, epidermal
growth factor, fibrinogen, interleukin-12 subunit p40, placenta
growth factor, serum glutamic oxaloacetic transaminase and
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thrombopoietin) were log transformed to improve the fit of the
levels to the normal distribution. Description of methods used to
derive measurements of regional [11C] PiB-PET levels have been
given in Jagust et al. (2010) and (2011) previously [16,42]. In this
study a similar approach was taken by averaging over regional
[11C] PiB-PET measurements in parietal, frontal, anterior
cingulate and precuneus regions of interest, to derive a global
measure of brain amyloid burden.
Data from either baseline or 12 months were used for these
cohorts, as described above, chosen to increase the number of
subjects with available data. Eighty four subjects (ADNI-PiB PET
cohort) had a [11C] PiB-PET scan 12 months after baseline, the
characteristics of this sample are shown in Table S1. Five hundred
and sixty six subjects (ADNI-RBM cohort) had RBM analytes
measured in plasma collected at baseline, the characteristics of this
sample at baseline is shown in Table S2. Seventy one subjects
(RBM-PiB PET cohort) had RBM analytes measured in plasma
collected 12 months after baseline and a [11C] PiB-PET scan
within a year of this, the characteristics of this sample at the date of
plasma collection is shown in Table 1. Converters from control to
MCI between plasma sample and [11C] PiB-PET scan date
account for the discrepancy in diagnostic groups between the
ADNI-PiB PET and RBM-PiB PET cohorts. Subject age was
determined based on the same dates.
Sample characteristics of each cohort by diagnostic group were
analysed in R [43]. Many continuous variables were not
distributed normally, and so are described by median and
interquartile range instead of mean and standard deviation, this
was also the reason that non-parametric statistical tests were used.
Continuous characteristics were tested for differences over
diagnostic groups by the non-parametric Kruskal-Wallis x2 test,
using kruskal.test in the R stats package. Discrete characteristics
were tested for differences over diagnostic groups by simulated
contingency table p-values, in the fisher.test function in the R stats
package, using 2,000 Monte Carlo samples.
MRI scan analysis
Dicom format MRI data was downloaded from the ADNI
website (www.loni.ucla.edu/ADNI). Data from 1.5 T scanners
was used with data collected from a variety of MR-systems with
protocols optimised for each type of scanner. The MRI protocol
included a high resolution sagittal 3D T1-weighted MPRAGE
volume (voxel size 1.161.161.2 mm3) acquired using a custom
pulse sequence specifically designed for the ADNI study to ensure
compatibility across scanners. Full brain and skull coverage was
required for the MRI datasets and detailed quality control carried
out on all MR images according to previously published quality
control criteria [44,45].
We applied the Freesurfer pipeline (version 4.5.0) to the MRI
images to produce regional cortical thickness and volumetric
measures as previously described [46] to produce hippocampal
and entorhinal cortex volumes, as well as entorhinal cortical
thickness. All volumetric measures from each subject were
normalised by the subjects intracranial volume. Cortical thickness
measures were not normalised [47] and were used in their raw
form.
Correlation analysis
R was used to analyse SRC and partial SRC, using cor.test in
the stats package and pcor.test in the ppcor package [48]
respectively. Partial correlations were used to take into account
subjects: age, gender, years of education, number of APOE E 4
alleles and the number of days separating the date of [11C]-PiB
PET scan and plasma sample. In the case of correlations between
RBM analytes and CSF Ab, ADAS-cog 13 or MRI features,
subjects whose relevant data was missing were excluded. RBM
analytes were clustered based upon (1 – their partial SRC) using
the R function hclust in the stats package with default settings, and
displayed using function heatmap.2 from the R gplots package
[49].
Linear regression
Linear regression was performed using the lm function in the R
stats package. This was appropriate because although many
variables were not distributed normally, the residuals of the
regression models used were approximately. Before regression,
measurements of each RBM analyte were transformed to a
standard deviation of one to allow each analyte to have equal
influence on the model (but not transformed to a mean of zero, to
make the analysis more comparable with that used in Thambisetty
et al. (2010) [14]). LOO CV was performed by fitting linear
regression models to the data, leaving out one subject at a time,
and using the model to predict brain amyloid burden in that
subject based on the fitted model. LOO CV R2 was calculated as
the square of the Pearson’s correlation coefficient, calculated using
cor.test, between the predicted and observed brain amyloid
burden.
A cut-off of 1.5 was used to dichotomise brain amyloid burden
in the RBM-PiB PET cohort as PiB positive (49 subjects) or
negative (22 subjects), as previously suggested by Jagust et al.
(2010) [16]. Predicted values were similarly dichotomised.
Sensitivity and specificity of this prediction was calculated in R
using epi.test in the epiR package [50].
Permutation tests were performed by permuting brain amyloid
burden across subjects in the data, and re-calculating the LOO
CV R2 that was achieved by fitting the regression model to the
resulting data. 100,000 permutations were used, and the number
of cases in which the LOO CV R2 exceeded that achieved with
the original dataset was recorded. Relative importance was
calculated using the LMG score [51], using the R package
relaimpo [52].
Independent cohort data for validation of the effect of
APOE E 4 genotype on APOE level in plasma
EDTA plasma samples from fasted subjects were obtained from
two independent cohorts: ANM a multicentre European study
across six centres [53] and KHPDCR a UK based study. The
combined cohort contained 269 control, 163 MCI and 262 AD
subjects. APOE genotype was determined using DNA extracted
from blood leukocytes by a standard phenol-chloroform extrac-
tion. The three main alleles APOE E 2, APOE E 3 and APOE E 4
differ at two residues, so consist of a two single nucleotide
polymorphism (SNP) haplotype. The SNPs rs429358 and rs7412
were genotyped and the allele inferred. SNPs were determined by
allelic discrimination assays based on fluorogenic 59 nuclease
activity. TaqMan SNP genotyping assays were performed on an
ABI Prism 7900HT and analyzed using SDS software, according
to the manufacturer’s instructions (Applied Biosystems, Warring-
ton, UK). 199 control, 103 MCI and 120 AD subjects were found
to have 0 APOE E 4 alleles. 65 control, 56 MCI and 112 AD
subjects were found to have 1 APOE E 4 alleles. 5 control, 4 MCI
and 30 AD subjects were found to have 2 APOE E 4 alleles. The
Human Neurodegenerative Panel 1 (7-plex) Cat. HNDG1-36K
MILLIPLEX MAP multiplex panels, developed by Merck
Millipore, was used to measure APOE level in plasma.
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Supporting Information
Figure S1 Distribution of brain amyloid burden. A
stacked histogram showing the distribution of brain amyloid
burden for different diagnostic groups. Control (dark blue), MCI
(green) and AD (red) represent subjects who remained in these
diagnostic groups throughout follow up period. Control/MCI
(light blue) and MCI/AD (orange) represents subjects whose
diagnosis converted between these groups during the follow up
period. Brain amyloid burden is in relative units.
(TIF)
Table S1 Characteristics of the ADNI-PiB PET cohort
by diagnostic group. P-values were calculated when appropri-
ate for differences across diagnostic groups, using a Kruskal-Wallis
x2 test for continuous characteristics and simulated contingency
table p-values for discrete characteristics.
(PDF)
Table S2 Characteristics of the ADNI-RBM cohort by
diagnostic group. P-values were calculated when appropriate
for differences across diagnostic groups, using a Kruskal-Wallis x2
test for continuous characteristics and simulated contingency table
p-values for discrete characteristics.
(PDF)
Table S3 Association of markers with AD phenotypes.
(PDF)
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